Andrographis für Upper Respiratory Tract Infections
B Evidenz Mindestens eine randomisierte Studie unterstützt dies, mit überwiegend konsistenten Ergebnissen.Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'immunecited.com';
const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Fazit
Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
Key Study Findings
Randomized Controlled Trial
n=331
1.0 weeks
Double-blind
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …
Dose: 200 mg/day
vs.: placebo
Outcome: URTI symptom severity
Wirkung: None
p = 0.034
Population: Participants with uncomplicated URTI
Review
A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …
Dose: None
vs.: None
Outcome: URTI symptom severity
Wirkung: None
None
Population: COVID-19/URTI patients
Review
Plant-Based Support of Respiratory Health during Viral Outbreaks.
Dose: None
vs.: None
Outcome: None
Wirkung: None
None
Population: None
Other
n=179
Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.
Dose: 60 mg
vs.: placebo
Outcome: None
Wirkung: None
p = 0.0053
Population: None
Meta-Analysis
n=1000
Safety of Andrographis paniculata: A systematic review and meta-analysis.
Dose: 95%
vs.: control
Outcome: None
Wirkung: None
None
Population: upper respiratory tract infection
Other
In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.
Dose: 6 μg/mL
vs.: Control group
Outcome: None
Wirkung: None
None
Population: None
Key Statistics
7
Studien
800
Teilnehmer
↑
Positive
B
Bewertung
Referenced Papers
Complementary therapies in …
2023
6 Zitierungen
Molecules (Basel, Switzerland)
2022
80 Zitierungen
Journal of agricultural …
2022
9 Zitierungen
Pharmacoepidemiology and drug …
2021
32 Zitierungen
Journal of traditional …
2021
9 Zitierungen
Brazilian journal of …
2020
45 Zitierungen
Cell death & …
2019
160 Zitierungen
Biomedicine & pharmacotherapy …
2019
103 Zitierungen
Phytomedicine : international …
2010
107 Zitierungen
Alternative medicine review …
2007
163 Zitierungen
American journal of …
2006
51 Zitierungen
Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy.
Systematic Review
Planta medica
2004
262 Zitierungen
Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials.
Systematic Review
Journal of clinical …
2004
157 Zitierungen
Primary care
2002
56 Zitierungen
Journal of the …
1990
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Übliche Dosierungen
- acute:
- 400 mg 3x/day for up to 7 days
- general:
- 200 mg standardized extract (30% andrographolides) 2x/day
Obergrenze: No established UL; short-term use (<14 days)
In der Forschung untersuchte Dosierungen
| Dosierung | Dauer | Wirkung | N |
|---|---|---|---|
| 200 mg/day | 1.0 weeks | Positive | 331 |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| 60 mg | -- | Positive | 179 |
| 95% | -- | Neutral | 1000 |
| 6 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| 18 G | 4.0 weeks | Mixed | -- |
Beste Einnahmezeit: At first sign of symptoms; with meals
Safety & Side Effects
Gemeldete Nebenwirkungen
- ⚠ Gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Headache
- ⚠ Fatigue
- ⚠ Allergic reactions (rare)
- ⚠ Potential anti-fertility effects (high doses in animal studies)
Bekannte Wechselwirkungen
- ● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
- ● Antihypertensive medications (additive blood pressure lowering)
- ● Immunosuppressant medications (may counteract immunosuppression)
Tolerierbare Höchstaufnahmemenge: No established UL; short-term use (<14 days)
Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.
Frequently Asked Questions
Does Andrographis help with Upper Respiratory Tract Infections?
Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).
How much Andrographis should I take for Upper Respiratory Tract Infections?
Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Andrographis?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.
Related Evidence
Andere Inhaltsstoffe für Upper Respiratory Tract Infections
References
- [1] Jeffrey Pradeep Raj et al.. Complement Ther Med. 2023. Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … doi:10.1016/j.ctim.2023.102934 PubMed
- [2] Aekkhaluck Intharuksa et al.. Molecules. 2022. A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. doi:10.3390/molecules27144479 PubMed
- [3] Thirumurugan Rathinasabapathy et al.. J Agric Food Chem. 2022. Plant-Based Support of Respiratory Health during Viral Outbreaks. doi:10.1021/acs.jafc.1c06227 PubMed
- [4] Wiwan Worakunphanich et al.. Pharmacoepidemiol Drug Saf. 2021. Safety of Andrographis paniculata: A systematic review and meta-analysis. doi:10.1002/pds.5190 PubMed
- [5] Mikayel Narimanyan et al.. J Tradit Complement Med. 2021. Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. doi:10.1016/j.jtcme.2021.06.001 PubMed
- [6] Moumita Majumdar et al.. Braz J Microbiol. 2020. In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. doi:10.1007/s42770-019-00169-0 PubMed
- [7] Jian Gao et al.. Cell Death Dis. 2019. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. doi:10.1038/s41419-019-2195-8 PubMed
- [8] Jiashu Lu et al.. Biomed Pharmacother. 2019. A review for the neuroprotective effects of andrographolide in the central nervous system. doi:10.1016/j.biopha.2019.109078 PubMed
- [9] R C Saxena et al.. Phytomedicine. 2010. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … doi:10.1016/j.phymed.2009.12.001 PubMed
- [10] Mario Roxas et al.. Altern Med Rev. 2007. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. PubMed
- [11] Roxane R Carr et al.. Am J Health Syst Pharm. 2006. Complementary and alternative medicine for upper-respiratory-tract infection in children. doi:10.2146/ajhp040613 PubMed
- [12] Joanna Thompson Coon et al.. Planta Med. 2004. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. doi:10.1055/s-2004-818938 PubMed
- [13] N Poolsup et al.. J Clin Pharm Ther. 2004. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. doi:10.1046/j.1365-2710.2003.00534.x PubMed
- [14] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
- [15] A Leelarasamee et al.. J Med Assoc Thai. 1990. Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. PubMed
FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.